Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03548779 · ClinicalTrials.gov registry record · NA
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 548
- Enrollment target
NCT03548779 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 548 participants.
The verdict
NCT03548779, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 548 participants
- Enrollment target
Study Summary
The "North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family well-being as well as diagnostic efficacy, management planning, and medical outcomes. A clinical trial will be implemented to compare (1) first-line exome sequencing to usual care and (2) participant pre-visit preparation to no pre-visit preparation. The study will use a randomized controlled design, with 2x2 factorial design, coupled with patient-reported outcomes and comprehensive clinical data collection addressing key outcomes, to determine the net impact of diagnostic results and secondary findings.
Interventions
- BEHAVIORAL Pre-visit prep
- DIAGNOSTIC_TEST usual care + exome seq
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 548 participants |
| Start Date | 2018-09-28 |
| Est. Completion | 2024-09-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03548779
The ClinicalTrials.gov registry entry for NCT03548779 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 548 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pre-visit prep is the first listed.
NCT03548779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03548779 about?
NCT03548779 is a clinical study titled "North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2". The "North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family well-being as well as diagnostic efficacy, management planning, and me...
What is the current status of trial NCT03548779?
This trial is currently completed. It is a NA study. The enrollment target is 548 participants. The study started on 2018-09-28. Estimated completion is 2024-09-08.
What interventions are being tested in trial NCT03548779?
The interventions under investigation include: Pre-visit prep (BEHAVIORAL), usual care + exome seq (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03548779?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.